What Is the Evidence for Omega-3 Fatty Acids in Cardiovascular and Cognitive Health?

The short answer

High-dose icosapentaenoic acid (EPA, 4g/day as icosapent ethyl) reduced major cardiovascular events by 25% in the REDUCE-IT trial. Standard-dose omega-3 supplements (1g/day) did not significantly reduce cardiovascular events in the VITAL trial but were associated with reduced cardiovascular mortality in secondary analyses. Omega-3s have consistent anti-inflammatory effects and emerging evidence for cognitive protection.

What the evidence actually shows

The REDUCE-IT trial (Bhatt et al., 2019, NEJM) randomised 8,179 high-risk patients on statins to icosapent ethyl (4g/day EPA) or placebo. The EPA group had a 25% relative risk reduction in major cardiovascular events. The VITAL trial (Manson et al., 2019, NEJM) randomised 25,871 adults to 1g/day omega-3 or placebo and found no significant reduction in major cardiovascular events overall, but did find a 28% reduction in myocardial infarction. Calder (2020) reviewed the anti-inflammatory mechanisms of EPA and DHA, noting their roles in producing specialised pro-resolving mediators (resolvins, protectins) that actively resolve inflammation.

"High-dose EPA (4g/day) reduced major cardiovascular events by 25% in patients with elevated triglycerides on statin therapy."

— Bhatt et al., NEJM 2019 (REDUCE-IT)

What the major health authorities say

MedlinePlus identifies omega-3 fatty acids as important for heart health and notes that they are found in fatty fish (salmon, mackerel, sardines), flaxseeds, and walnuts. The NIH Office of Dietary Supplements recommends consuming fatty fish twice per week as the primary dietary source. The American Heart Association recommends omega-3 supplements for patients with established cardiovascular disease or elevated triglycerides. The NIA notes that omega-3s are being studied for their potential role in reducing dementia risk.

Practical implications

For most healthy adults, consuming fatty fish (salmon, mackerel, sardines, herring) 2–3 times per week provides approximately 1–2g of EPA+DHA per day and is the most evidence-supported approach. For individuals with elevated triglycerides (>500 mg/dL) or established cardiovascular disease, prescription-grade high-dose EPA (icosapent ethyl, 4g/day) has the strongest evidence. Standard over-the-counter fish oil supplements (1g/day) have weaker cardiovascular evidence but are reasonable for their anti-inflammatory effects. Algae-derived omega-3s are an equivalent plant-based alternative.

Where reasonable people still disagree

• Whether the REDUCE-IT results are fully attributable to EPA or partially to the mineral oil placebo causing adverse effects in the control group — a methodological controversy.
• Whether DHA provides equivalent cardiovascular benefits to EPA, or whether EPA-only formulations are superior.
• The optimal dose and formulation of omega-3 for cognitive protection in older adults.